Literature DB >> 17997086

A novel peptide sequence in perlecan domain IV supports cell adhesion, spreading and FAK activation.

Mary C Farach-Carson1, Anissa J Brown, Megan Lynam, Jeffrey B Safran, Daniel D Carson.   

Abstract

Perlecan/HSPG2 is a large, multi-domain, multifunctional heparan sulfate proteoglycan with a wide tissue distribution. With the exception of its unique domain I, each of perlecan's other four domains shares sequence similarity to other protein families including low density lipoprotein (LDL) receptor, laminin alpha chain, neural cell adhesion molecule (NCAM), immunoglobulin (Ig) superfamily members, and epidermal growth factor (EGF). Previous studies demonstrated that glycosaminoglycan-bearing perlecan domain I supports early chondrogenesis and growth factor delivery. Other sites in the core protein interact with other matrix molecules and support cell adhesion, although the peptide sequences involved remain unidentified. To identify novel functional motifs within perlecan, we used a bioinformatics approach to predict regions likely to be on the exterior of the folded protein. Unique hydrophilic sequences of about 18 amino acids were selected for testing in cell adhesion assays. A novel peptide sequence (TWSKVGGHLRPGIVQSG) from an immunoglobulin (Ig) repeat in domain IV supported rapid cell adhesion, spreading and focal adhesion kinase (FAK) activation when compared to other peptides, a randomly scrambled sequence of the domain IV peptide or a negative control protein. MG-63 human osteosarcoma cells, epithelial cells and multipotent C(3)H10T1/2 cells, but not bone marrow cells, rapidly, i.e., within 30 min, formed focal adhesions and assembled an actin cytoskeleton on domain IV peptide. Cell lines differentially adhered to the domain IV peptide, suggesting adhesion is receptor specific. Adhesion was divalent cation independent and heparin sensitive, a finding that may explain some previously poorly understood observations obtained with intact perlecan. Collectively, these studies demonstrate the feasibility of using bioinformatics-based strategies to identify novel functional motifs in matrix proteins such as perlecan.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17997086      PMCID: PMC2276179          DOI: 10.1016/j.matbio.2007.09.007

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  40 in total

1.  Dyssegmental dysplasia, Silverman-Handmaker type, is caused by functional null mutations of the perlecan gene.

Authors:  E Arikawa-Hirasawa; W R Wilcox; A H Le; N Silverman; P Govindraj; J R Hassell; Y Yamada
Journal:  Nat Genet       Date:  2001-04       Impact factor: 38.330

2.  Perlecan participates in proliferation activation of quiescent Drosophila neuroblasts.

Authors:  Aaron Voigt; Ralf Pflanz; Ulrich Schäfer; Herbert Jäckle
Journal:  Dev Dyn       Date:  2002-08       Impact factor: 3.780

3.  Apoptosis of endothelial cells triggers a caspase-dependent anti-apoptotic paracrine loop active on VSMC.

Authors:  Marc-André Raymond; Anik Désormeaux; Patrick Laplante; Normand Vigneault; Janos G Filep; Karine Landry; Alexey V Pshezhetsky; Marie-Josée Hébert
Journal:  FASEB J       Date:  2004-02-20       Impact factor: 5.191

Review 4.  Integrins in epithelial cell polarity: using antibodies to analyze adhesive function and morphogenesis.

Authors:  Karl S Matlin; Brian Haus; Anna Zuk
Journal:  Methods       Date:  2003-07       Impact factor: 3.608

Review 5.  Basement membrane proteoglycans: from cellar to ceiling.

Authors:  Renato V Iozzo
Journal:  Nat Rev Mol Cell Biol       Date:  2005-08       Impact factor: 94.444

6.  Mapping of binding sites for nidogens, fibulin-2, fibronectin and heparin to different IG modules of perlecan.

Authors:  M Hopf; W Göhring; K Mann; R Timpl
Journal:  J Mol Biol       Date:  2001-08-17       Impact factor: 5.469

7.  Chondrogenic activity of the heparan sulfate proteoglycan perlecan maps to the N-terminal domain I.

Authors:  Margaret M French; Ronald R Gomes; Rupert Timpl; Magnus Höök; Kirk Czymmek; Mary C Farach-Carson; Daniel D Carson
Journal:  J Bone Miner Res       Date:  2002-01       Impact factor: 6.741

Review 8.  Role of perlecan in skeletal development and diseases.

Authors:  John Hassell; Yoshihiko Yamada; Eri Arikawa-Hirasawa
Journal:  Glycoconj J       Date:  2002 May-Jun       Impact factor: 2.916

9.  Some effects of the essential fatty acids linoleic acid and alpha-linolenic acid and of their metabolites gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid, and of prostaglandins A1 and E1 on the proliferation of human osteogenic sarcoma cells in culture.

Authors:  J Booyens; P Engelbrecht; S le Roux; C C Louwrens; C F Van der Merwe; I E Katzeff
Journal:  Prostaglandins Leukot Med       Date:  1984-07

10.  Perlecan and its immunoglobulin like domain IV are abundant in vitreous and serum of the chick embryo.

Authors:  Manimalha Balasubramani; Mark E Bier; Susanna Hummel; Wolfgang J Schneider; Willi Halfter
Journal:  Matrix Biol       Date:  2004-06       Impact factor: 11.583

View more
  23 in total

1.  Superficial dermal fibroblasts enhance basement membrane and epidermal barrier formation in tissue-engineered skin: implications for treatment of skin basement membrane disorders.

Authors:  Mathew Varkey; Jie Ding; Edward E Tredget
Journal:  Tissue Eng Part A       Date:  2013-10-17       Impact factor: 3.845

Review 2.  The nature and biology of basement membranes.

Authors:  Ambra Pozzi; Peter D Yurchenco; Renato V Iozzo
Journal:  Matrix Biol       Date:  2016-12-28       Impact factor: 11.583

Review 3.  Insidious changes in stromal matrix fuel cancer progression.

Authors:  Fayth L Miles; Robert A Sikes
Journal:  Mol Cancer Res       Date:  2014-01-22       Impact factor: 5.852

Review 4.  The role of perlecan and endorepellin in the control of tumor angiogenesis and endothelial cell autophagy.

Authors:  Stephen Douglass; Atul Goyal; Renato V Iozzo
Journal:  Connect Tissue Res       Date:  2015-07-16       Impact factor: 3.417

5.  The role of vascular-derived perlecan in modulating cell adhesion, proliferation and growth factor signaling.

Authors:  Megan S Lord; Christine Y Chuang; James Melrose; Michael J Davies; Renato V Iozzo; John M Whitelock
Journal:  Matrix Biol       Date:  2014-02-06       Impact factor: 11.583

Review 6.  Border patrol: insights into the unique role of perlecan/heparan sulfate proteoglycan 2 at cell and tissue borders.

Authors:  Mary C Farach-Carson; Curtis R Warren; Daniel A Harrington; Daniel D Carson
Journal:  Matrix Biol       Date:  2013-08-31       Impact factor: 11.583

7.  Biomaterials-based strategies for salivary gland tissue regeneration.

Authors:  Tugba Ozdemir; Eric W Fowler; Ying Hao; Anitha Ravikrishnan; Daniel A Harrington; Robert L Witt; Mary C Farach-Carson; Swati Pradhan-Bhatt; Xinqiao Jia
Journal:  Biomater Sci       Date:  2016-02-15       Impact factor: 6.843

8.  Perlecan domain I-conjugated, hyaluronic acid-based hydrogel particles for enhanced chondrogenic differentiation via BMP-2 release.

Authors:  Amit K Jha; Weidong Yang; Catherine B Kirn-Safran; Mary C Farach-Carson; Xinqiao Jia
Journal:  Biomaterials       Date:  2009-09-23       Impact factor: 12.479

Review 9.  Multifunctionality of extracellular and cell surface heparan sulfate proteoglycans.

Authors:  Catherine Kirn-Safran; Mary C Farach-Carson; Daniel D Carson
Journal:  Cell Mol Life Sci       Date:  2009-07-24       Impact factor: 9.261

10.  Perlecan domain IV peptide stimulates salivary gland cell assembly in vitro.

Authors:  Swati Pradhan; Chu Zhang; Xinqiao Jia; Daniel D Carson; Robert Witt; Mary C Farach-Carson
Journal:  Tissue Eng Part A       Date:  2009-11       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.